二十胺 | 10525-37-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 二十胺
• 中文别名: 二十烷基胺；正二十烷胺
• 英文名称: 1-aminoeicosane
• 英文别名: eicosylamine；n-Eicosylamin；Eicosanylamine；1-Eicosanamine；icosan-1-amine
• CAS: 10525-37-8
• 化学式: C₂₀H₄₃N
• 分子量: 297.568
• InChiKey: BUHXFUSLEBPCEB-UHFFFAOYSA-N

物化性质

• 熔点：
  57.8℃
• 沸点：
  369.05°C (estimate)
• 密度：
  0.7993 (estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  9.6
• 重原子数：
  21
• 可旋转键数：
  18
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2921199090
• 储存条件：
  2-8°C，干燥

反应信息

• 作为反应物：
  描述：

  二十胺 在 sodium tetrahydroborate 、 magnesium sulfate 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 4.0h， 生成 N,N-di-n-archidylamine
  参考文献：
  名称：

  Anchor Dependency for Non-Glycerol Based Cationic Lipofectins: Mixed Bag of Regular and Anomalous Transfection Profiles

  摘要：

  Although detailed structure activity, physicochemical and biophysical investigations in probing the anchor influence in liposomal gene delivery have been reported for glycerol-based transfection lipids, the corresponding investigation for non-glycerol based simple monocationic transfection lipids have not yet been undertaken. Towards this end, herein, we delineate our structure - activity and physicochemical approach in deciphering the anchor dependency in liposomal gene delivery using fifteen new structural analogues (lipids 1 - 15) of recently reported nonglycerol based monocationic transfection lipids. The C-14 analogues in both series 1 (lipids 1 - 6) and series 2 (lipids 7-15) showed maximum efficiency in transfecting COS-1 and CHO cells. However, the C-12 analogue of the ether series (lipid 3) exhibited a seemingly anomalous behavior compared with its transfection efficient C-10 and C-14 analogues (lipids 2 and 4) in being completely inefficient to transfect both COS-1 and CHO cells. The present structure - activity investigation also convincingly demonstrates that enhancement of transfection efficiencies through incorporation of membrane reorganizing unsaturation elements in the hydrophobic anchor of cationic lipids is not universal but cell dependent. The strength of the interaction of lipids 1 - 15 with DNA was assessed by their ability to exclude ethidium bromide bound to the DNA. Cationic lipids with long hydrophobic tails were found, in general, to be efficient in excluding EtBr from DNA. Gel to liquid crystalline transition temperatures of the lipids was measured by fluorescence anisotropy measurement technique. In general (lipid 2 being an exception), transfection efficient lipids were found to have their mid transition temperatures at or below physiological temperatures (37degreesC).

  DOI：

  10.1002/1521-3765(20020215)8:4<900::aid-chem900>3.0.co;2-x
• 作为产物：
  描述：

  溴代二十烷 在 potassium carbonate 、 甲胺 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 20.0h， 生成 二十胺
  参考文献：
  名称：

  烷基链长和氢键对2-噻吩型二芳烃在液体/高取向热解石墨（HOPG）界面上的协同自组装的影响

  摘要：

  正确理解自组装过程对于在具有功能分子的2D表面上定制纳米结构的顺序至关重要。光致变色化合物是高级光响应性表面构件的有希望的候选者。为了研究分子结构与有序形成机理之间的关系，合成了通过酰胺基或酯基连接的各种长度的烷基侧链的2-噻吩基型二蒽。通过扫描隧道显微镜（STM）研究了它们在液体/固体界面的自组装。成核平衡常数（：表面覆盖的浓度依赖性通过使用合作模式为基于两个特征参数2D表面分析ķ Ñ）和伸长率平衡常数（K e）。可以得出以下结论。1）通过STM观察到稳定的2D分子有序排列的浓度随着烷基链长度的增加呈指数下降。2）带有酰胺基的化合物比带有酯基的化合物在2D表面上具有更高的自组装性（即σ，定义为K n / K e）。3）酯衍生物的开环异构体的自组装过程接近等当性，而闭环异构体的自组装过程是协作的，因为成核步骤的平衡常数不同（即，K n）之间的两个异构体。

  DOI：

  10.1002/chem.201500707

文献信息

• Mononuclear iron complex and organic synthesis reaction using same
  申请人：KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION

  公开号：US10363551B2

  公开（公告）日：2019-07-30

  A mononuclear iron bivalent complex having iron-silicon bonds, which is represented by formula (1), can exhibit an excellent catalytic activity in at least one reaction selected from three reactions, i.e., a hydrosilylation reaction, a hydrogenation reaction and a reaction for reducing a carbonyl compound. (In the formula, R1 to R6 independently represent a hydrogen atom, an alkyl group which may be substituted by X, or the like; X represents a halogen atom, or the like; L1 represents at least one two-electron ligand selected from an isonitrile ligand, an amine ligand, an imine ligand, a nitrogenated heterocyclic ring, a phosphine ligand, a phosphite ligand and a sulfide ligand, wherein, when multiple L1's are present, two L1's may be bonded to each other; L2 represents a two-electron ligand that is different from a CO ligand or the above-mentioned L1, wherein, when multiple L2's are present, two L2's may be bonded to each other; and m1 represents an integer of 1 to 4 and m2 represents an integer of 0 to 3, wherein the sum total of m1 and m2 (i.e., m1+m2) satisfies 3 or 4.)

  具有铁-硅键的单核二价铁络合物，其由公式（1）表示，可以在三个反应中选择至少一个反应表现出优异的催化活性，即硅氢化反应、氢化反应和还原羰基化合物的反应。 （在公式中，R1至R6独立代表氢原子、可能被X取代的烷基团等；X代表卤素原子等；L1代表至少一种从异腈配体、胺配体、亚胺配体、氮杂环、膦配体、亚磷酸盐配体和硫化物配体中选择的两电子配体，其中，当存在多个L1时，两个L1可以相互连接；L2代表与CO配体或上述L1不同的两电子配体，其中，当存在多个L2时，两个L2可以相互连接；m1代表1至4的整数，m2代表0至3的整数，其中m1和m2的总和（即m1+m2）满足3或4。）
• MONONUCLEAR IRON COMPLEX AND ORGANIC SYNTHESIS REACTION USING SAME
  申请人：KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION

  公开号：US20160023196A1

  公开（公告）日：2016-01-28

  Provided is a mononuclear iron complex that comprises an iron-silicon bond that is represented by formula (1) and that exhibits excellent catalyst activity in each of a hydrosilylation reaction, a hydrogenation reaction, and reduction of a carbonyl compound. In formula (1), R 1 -R 6 either independently represent an alkyl group, an aryl group, an aralkyl group or the like that may be substituted with a hydrogen atom or X, or represent a crosslinking substituent in which at least one pair comprising one of R 1 -R 3 and one of R 4 -R 6 is combined. X represents a halogen atom, an organoxy group, or the like. L represents a two-electron ligand other than CO. When a plurality of L are present, the plurality of L may be the same as or different from each other. When two L are present, the two L may be bonded to each other. n and m independently represent an integer of 1 to 3 with the stipulation that n+m equals 3 or 4.

  提供的是一种含有铁硅键的单核铁配合物，其由式（1）表示，并且在氢硅烷基化反应、加氢反应和醛类化合物还原反应中表现出优异的催化活性。 在式（1）中，R1-R6分别独立表示可以用氢原子或X取代的烷基、芳基、芳基烷基等，或表示至少包括一个由R1-R3和一个由R4-R6组成的一对的交联取代基。X表示卤素原子、有机氧基等。L表示除CO之外的双电子配体。当存在多个L时，这些L可以相同也可以不同。当存在两个L时，这两个L可以与彼此相连。n和m分别表示1到3的整数，且n+m等于3或4。
• PROCESS FOR PREPARING AMINES BY HOMOGENEOUSLY CATALYZED ALCOHOL AMINATION IN THE PRESENCE OF A COMPLEX CATALYST COMPRISING IRIDIUM AND AN AMINO ACID
  申请人：BASF SE

  公开号：US20140046054A1

  公开（公告）日：2014-02-13

  The invention relates to a process for preparing amines (A) by alcohol amination of alcohols (Al) by means of an aminating agent (Am) with elimination of water, wherein the alcohol amination is carried out in the presence of a complex catalyst comprising iridium and an amino acid.

  该发明涉及一种通过醇胺化剂（Am）在消除水的情况下，通过醇（Al）的醇胺化制备胺（A）的过程，其中醇胺化在铱和氨基酸组成的复合催化剂存在下进行。
• ALKYNYL-SUBSTITUTED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF
  申请人：BEIJING INNOCARE PHARMA TECH CO., LTD.

  公开号：US20190210997A1

  公开（公告）日：2019-07-11

  The present invention relates to an alkynyl-substituted heterocyclic compound acting as an FGFR inhibitor, a preparation method therefor and a medical use thereof. In particular, the present invention relates to a compound as shown in general formula (I) and a pharmaceutically acceptable salt thereof; a pharmaceutical composition including the compound or a pharmaceutically acceptable salt thereof; a method for treating and/or preventing FGFR-associated diseases, particularly tumors, by using the compound or a pharmaceutically acceptable salt thereof; and a preparation method for the compound or a pharmaceutically acceptable salt thereof. The present invention also relates to the use of the compound or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition including the compound or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating and/or preventing FGFR-associated diseases, particularly tumors, wherein the definition of each substituent group in general formula (I) is the same as that in the description.

  本发明涉及一种作为FGFR抑制剂的炔基取代杂环化合物，其制备方法及医药用途。具体而言，本发明涉及一种如一般式（I）所示的化合物及其药学上可接受的盐；包括该化合物或其药学上可接受的盐的药物组合物；通过使用该化合物或其药学上可接受的盐来治疗和/或预防FGFR相关疾病，特别是肿瘤的方法；以及该化合物或其药学上可接受的盐的制备方法。本发明还涉及使用该化合物或其药学上可接受的盐，或包括该化合物或其药学上可接受的盐的药物组合物来制备用于治疗和/或预防FGFR相关疾病，特别是肿瘤的药物，其中一般式（I）中每个取代基团的定义与描述中的相同。
• 长链胺取代的二甲基苯铵类化合物、制备、自组装结构及用途
  申请人：四川大学华西医院

  公开号：CN110092731B

  公开（公告）日：2022-03-04

  长链胺取代的二甲基苯铵类化合物、制备、自组装结构及用途。该类化合物能具有超长效麻醉效应，神经病理损伤低，是一类长链胺取代的N‑二乙氨基乙酰‑2,6‑二甲基苯铵化合物，结构如式(Ⅰ)所示，以及该类化合物的盐，结构如式(Ⅱ)所示。该化合物可在含水溶剂中自组装形成包括球形胶束、Janus胶束以及囊泡在内的微观粒子，在生物体内可发挥长时间局部麻醉作用，局麻和/或镇痛作用时间可超过120小时，神经病理损伤低，安全性远远高于已公开的长效局麻化合物。